Physician profile
Cory James Lappin
NPI 1629561204
$366,504.75
in general payments reported to CMS, 2019-2025
30 companies · $260K in 2025
The $260K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,252 · 2020: $414 · 2021: $906 · 2022: $1,165 · 2023: $13K · 2024: $91K · 2025: $260K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $159K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $67K · Consulting Fee: $64K · Travel and Lodging: $38K · Food and Beverage: $35K · Education: $27.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $159,131.21 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $66,587.50 |
| Consulting Fee | $64,155.00 |
| Travel and Lodging | $37,831.47 |
| Food and Beverage | $35,034.46 |
| Education | $27.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $188,793.41 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $78,659.22 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $48,208.63 | 2021-2025 | Tryptyr, Precision 7, Precision 1 |
| Lumenis Be INC | $18,696.60 | 2023-2025 | M22, Optilight |
| Harrow Eye, LLC | $9,798.04 | 2025 | Vevye |
| Alcon Research LLC | $7,475.00 | 2024-2025 | Tryptyr |
| Dompe US, INC. | $6,508.56 | 2019-2025 | Oxervate |
| Nordic Pharma, INC. | $2,100.00 | 2025 | Lacrifill |
| Oyster Point Pharma, INC. | $1,829.89 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $1,661.90 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Novartis Pharmaceuticals Corporation | $656.73 | 2019-2023 | |
| Sight Sciences, INC. | $352.92 | 2019-2025 | Tearcare System |
| Coopervision INC. | $311.59 | 2022-2023 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $197.30 | 2019-2021 | |
| Biotissue Holdings INC. | $186.62 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $158.91 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $133.98 | 2024 | Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $122.04 | 2019 | |
| Shire North American Group INC | $113.24 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $112.32 | 2019 | |
| Mallinckrodt Enterprises LLC | $107.32 | 2019 | |
| Glaukos Corporation | $104.92 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $58.14 | 2021-2022 | |
| Thea Pharma INC. | $32.58 | 2024 | |
| Mallinckrodt Hospital Products INC. | $26.67 | 2025 | Acthar |
| The Walman Optical Company | $23.81 | 2019 | |
| Maculogix, INC. | $21.53 | 2021 | |
| Lkc Technologies, INC. | $18.84 | 2024 | |
| Akorn Operating Company LLC | $18.10 | 2021 | |
| Alimera Sciences, INC. | $15.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Lappin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.